Wall Street Transcript Interview with Randall E. Woods, the President and CEO of Sophiris Bio Inc. (SPHS)

April 25, 2014

67 WALL STREET, New York - April 25, 2014 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Biotechnology and Pharmaceutical Companies Valuation - Genetic and Cell Therapies

Companies include: Sophiris Bio Inc. (SPHS) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President and CEO of Sophiris Bio Inc. (SPHS) discusses company strategy and the outlook for this vital industry:

TWST: Can you give us an update on the PRX302 trial, what is it intended to do, and how is that going?

Mr. Woods: PRX302 is a drug we're developing to treat BPH. As men advance in age, excessive tissue growth occurs in the prostate, and it's this excessive tissue growth that puts pressure on the urethra, constricting the flow of urine, which causes lower-urinary-tract-type symptoms that are representative of BPH. These symptoms are usually irritative and obstructive in nature, and often include frequent nighttime urination. The frequent nighttime urination, known as nocturia, is the condition that sends many men in to see their physicians. This condition can have a profound impact on their quality of life. And in fact, if you've ever talked to a man who has BPH, he'll tell you that he's miserable, and that the treatment options available today are not satisfactory. You have a lot of men who are actually actively seeking a new treatment for BPH.

TWST: You mentioned that the treatments today are generally not considered satisfactory by patients. Could you give us an overview of the competitive treatments and the downsides or upsides of those treatments?

Mr. Woods: Sure, I'd be glad to. First, nearly all of the current treatments on the market carry the potential for causing sexual dysfunction or other serious side effects. When a BPH patient initially presents to the urologist, there are a couple of things the urologist thinks about. First, how really bothered is that patient by their symptoms, and secondly, how large is the prostate. Usually what will happen is the physician will prescribe some type of oral medication.

There are really two different classes of drugs that get prescribed. One is called an alpha-blocker, which actually relaxes the smooth muscle around the neck of the bladder and helps restore some of that urinary flow. The patient gets some pretty quick symptomatic relief. There is another class of drugs called the 5-alpha-reductase inhibitors. Those will normally decrease the size of the prostate, but the issue is that that can take as long as six months before the patient realizes any benefit; most men aren't that patient.

The downside to these is: one, if you think about these men, most of them are becoming more advanced in age. They're probably already on some oral medications, maybe an antihypertensive or anticholesterol, so the last thing they want to do is take another pill. There are also some cardiovascular adverse events, like dizziness and weakness, that are associated with the alpha-blockers, and as I mentioned earlier, both classes of drugs actually have the potential for causing sexual dysfunction side effects. That tends to be a major deterrent for most of these men.

So what happens is that...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.